LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy.BMC Cancer | PMID 40851062PMC12376434 | 2025-Aug-25 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies.RMD Open已检查 7 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other;另有 2 张未列出。 | PMID 40854810PMC12382576 | 2025-Aug-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.J Clin PsychiatryPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40875502无 PMCID | 2025-Aug-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40454634无 PMCID | 2025-Aug-21 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40454639无 PMCID | 2025-Aug-21 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40454642无 PMCID | 2025-Aug-21 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.Blood疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40499012无 PMCID | 2025-Aug-21 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40834301无 PMCID | 2025-Aug-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.J Clin Oncol | PMID 40623279PMC12352567 | 2025-Aug-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Revisiting the Effect of Udenafil on Exercise Performance in Patients With Fontan Circulation: Results of a Post Hoc Analysis of the FUEL Trial.J Am Heart Assoc已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。 | PMID 40792599PMC12533643 | 2025-Aug-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial.BMJ已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig 1:研究设计图;Fig 2:AI 判定为 flow diagram;Fig 3:生活质量量表图;Fig 4:AI 判定为 other;Fig 5:AI 判定为 other;另有 1 张未列出。 | PMID 40829896PMC12362199 | 2025-Aug-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of tildrakizumab in patients with early- vs. late-onset psoriasis.Br J Dermatol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40365708无 PMCID | 2025-Aug-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Radiotherapy quality assurance program of ongoing clinical trial using stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC): a dummy run study of a prospective, randomized, multicenter phase III trial (KGOG 3064/KROG 2204).BMC Cancer已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other。 | PMID 40826041PMC12362936 | 2025-Aug-18 | 0.95 | The report describes a dummy-run/quality assurance sub-study of an ongoing Phase III trial (SABR-ROC) to assess treatment planning consistency. It does not present the primary efficacy results of the trial, nor does it report any time-to-event outcomes (OS, PFS, etc.) or Kaplan-Meier analyses. Furthermore, the intervention is stereotactic ablative radiation therapy (SABR), which is a non-drug intervention, making the study ineligible based on the drug-intervention criterion. | 无 KM 图 |
| Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial.J Neurol已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other。 | PMID 40817977PMC12357813 | 2025-Aug-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40544432无 PMCID | 2025-Aug-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40544433无 PMCID | 2025-Aug-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| The efficacy and safety of SYN023 (Zamerovimab and Mazorelvimab injection), the recombinant humanized anti-rabies virus monoclonal antibody mixture, combined with rabies vaccine in a WHO category III rabies post-exposure population: A randomized, double-blind, positive control, phase III clinical trial.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40479926无 PMCID | 2025-Aug-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19).Vaccine已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:ROC 图;Figure 3:ROC 图;Figure 4:AI 判定为 other。 | PMID 40479932PMC12309408 | 2025-Aug-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Phase II/III randomized immunogenicity and safety study of a Brazilian meningococcal serogroup B vaccine in children.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40494223无 PMCID | 2025-Aug-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Noncontrast CT vs CT Perfusion Imaging in Patients With Basilar Artery Occlusion: Analysis of the ATTENTION and ATTENTION IA Trials.Neurology入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40674670无 PMCID | 2025-Aug-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy.J Am Coll CardiolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40769673无 PMCID | 2025-Aug-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B.J Am Coll CardiolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40769675无 PMCID | 2025-Aug-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Assessing participants' experiences with the COVID-19 symptom diary in a clinical trial.J Patient Rep Outcomes已检查 1 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other。 | PMID 40788441PMC12339813 | 2025-Aug-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIG 1.:森林图/亚组分析图;FIG 2.:非 KM 图。 | PMID 40561385PMC12316163 | 2025-Aug-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40783289无 PMCID | 2025-Aug-09 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| The efficacy and safety of inhaled peptide YKYY017 for COVID-19 patients with mild illness: a phase 2 randomized controlled trial.Nat Commun入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40775020PMC12332093 | 2025-Aug-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.Blood | PMID 40127397PMC13292241 | 2025-Aug-07 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40454637无 PMCID | 2025-Aug-07 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40454645无 PMCID | 2025-Aug-07 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Ciprofloxacin versus Aminoglycoside-Ciprofloxacin for Bubonic Plague.N Engl J Med已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 forest plot。 | PMID 40768716PMC7618094 | 2025-Aug-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients.Antimicrob Agents ChemotherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40530972PMC12327849 | 2025-Aug-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial.Antimicrob Agents Chemother | PMID 40552814PMC12327002 | 2025-Aug-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.Signal Transduct Target Ther | PMID 40769977PMC12329032 | 2025-Aug-06 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Phase II trial of intravenous human dental pulp stem cell therapy for Huntington's disease: a randomized, double-blind, placebo-controlled study.Stem Cell Res Ther入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40770775PMC12330078 | 2025-Aug-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial.JAMA已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:森林图/亚组分析图。 | PMID 40587141PMC12210145 | 2025-Aug-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA-MI Trial.J Am Heart Assoc | PMID 40728174PMC12449975 | 2025-Aug-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Heart Rhythm Monitoring Practices, Detection of Atrial Fibrillation, and Effect of Anticoagulation in the ARCADIA Trial.J Am Heart Assoc已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。 | PMID 40728193PMC12449994 | 2025-Aug-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of simenafil in men with erectile dysfunction: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group, phase 3 trial.J Sex MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40624775无 PMCID | 2025-Aug-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis.RMD Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PMC Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图;Figure 2:森林图/亚组分析图;Figure 3:森林图/亚组分析图;Figure 4:非 KM 图;Figure 5:非 KM 图;另有 2 张未列出。 | PMID 40759562PMC12323545 | 2025-Aug-04 | 0.90 | The study is a Phase III randomized trial with drug interventions, but it is not in oncology and does not report a primary or key secondary time-to-event efficacy endpoint. The focus is on biomarker analysis for treatment response in rheumatoid arthritis. | 无 KM 图 |
| Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40683287无 PMCID | 2025-Aug-02 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40683290无 PMCID | 2025-Aug-02 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40752909无 PMCID | 2025-Aug-02 | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 无 KM 图 |
| Estimation of the Harvey Bradshaw Index from the Patient-Reported Outcome 2 in Crohn's Disease: Results Based on a Large Scale Randomized Controlled Trial.Inflamm Bowel Dis已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other。 | PMID 39656815PMC12342735 | 2025-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS.Inflamm Bowel Dis已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:森林图/亚组分析图。 | PMID 39862395PMC12342783 | 2025-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-Term Effects of Extended-Release Pemafibrate Tablets on Dyslipidemia and Safety in Triglyceridemic Patients: A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group Study.J Atheroscler Thromb已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig.1. Disposition of patients:AI 判定为 flow diagram;Fig.2. Change in fasting serum TG levels:AI 判定为 other。 | PMID 39924184PMC12328711 | 2025-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial.Clin Cancer Res | PMID 40067142PMC7617601 | 2025-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab.Rheumatology (Oxford)已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:森林图/亚组分析图。 | PMID 40244828PMC12316369 | 2025-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical Trials.JAMA Oncol入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 40471585PMC12142471 | 2025-Aug-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial.JAMA Cardiol | PMID 40531488PMC12177723 | 2025-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy: A Preliminary Analysis of a Randomized Clinical Trial.JAMA Oncol已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure.:CONSORT/入组流程图。 | PMID 40531511PMC12177721 | 2025-Aug-01 | 0.90 | Eligible for oncology, human, randomized, Phase III, and original result criteria, but excluded because the intervention is non-drug (stereotactic radiation therapy) and the reported outcomes are focused on toxicity, feasibility, and logistics, not a primary/key secondary time-to-event efficacy endpoint. | 无 KM 图 |